Please ensure Javascript is enabled for purposes of website accessibility

Why Catalyst Pharmaceuticals Stock Broke Down Today

By George Budwell - Aug 8, 2019 at 3:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Catalyst's shares took a sizable hit this morning.

What happened

Shares of the rare-disease drugmaker Catalyst Pharmaceuticals (CPRX 1.30%) dipped by as much as 12.3% almost immediately out of the gate this morning in response to the company's second-quarter earnings release, which hit the wires after the closing bell on Tuesday.

What caused investors to hit the panic button? Catalyst's brief double-digit downturn this morning appears to be the result of short-sellers betting on another round of panic selling. The drugmaker, after all, is dealing with a significant competitive threat to its Lambert-Eaton myasthenic syndrome (LEMS) drug Firdapse, which isn't sitting well with Catalyst's shareholders.   

The words risk and safe spelled out in wooden block letters being balanced on a red seesaw sitting on a wooden table.

Image source: Getty Images.

So what

As Catalyst actually beat Wall Street's consensus estimates for both earnings per share and revenue in Q2 by a wide margin, it's not surprising that the drugmaker's shares have rebounded nicely over the course of today's trading session. In fact, its shares were only down by 2.3% as of 2:24 p.m. EDT. That's a big improvement compared to how Catalyst's shares started the day. 

Now what

The bad news is that Catalyst could be dealing with this competitive threat for at least the remainder of 2019. The company has filed suit against the Food and Drug Administration (FDA) and related parties over this unprecedented regulatory approval, but the legal process is notoriously slow. Short-sellers, in turn, will probably continue to use this particular risk factor to their advantage for the foreseeable future. 

On the bright side, Catalyst does have a solid rationale for suing the FDA, meaning that a favorable outcome is a real possibility in this case. So, if you're comfortable with short-term volatility, Catalyst's stock may be worth adding to your portfolio right now. After all, this tiny orphan drugmaker is trading at a steep discount relative to Firdapse's long-term commercial potential.    

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Catalyst Pharmaceuticals, Inc. Stock Quote
Catalyst Pharmaceuticals, Inc.
CPRX
$7.00 (1.30%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.